Methodological and ethical challenges in the use of focused ultrasound for blood-brain barrier disruption in neuro-oncology
© 2023. The Author(s)..
BACKGROUND: Focused ultrasound (FUS) shows promise for enhancing drug delivery to the brain by temporarily opening the blood-brain barrier (BBB), and it is increasingly used in the clinical setting to treat brain tumours. It remains however unclear whether FUS is being introduced in an ethically and methodologically sound manner. The IDEAL-D framework for the introduction of surgical innovations and the SYRCLE and ROBINS-I tools for assessing the risk of bias in animal studies and non-randomized trials, respectively, provide a comprehensive evaluation for this.
OBJECTIVES AND METHODS: A comprehensive literature review on FUS in neuro-oncology was conducted. Subsequently, the included studies were evaluated using the IDEAL-D framework, SYRCLE, and ROBINS-I tools.
RESULTS: In total, 19 published studies and 12 registered trials were identified. FUS demonstrated successful BBB disruption, increased drug delivery, and improved survival rates. However, the SYRCLE analysis revealed a high risk of bias in animal studies, while the ROBINS-I analysis found that most human studies had a high risk of bias due to a lack of blinding and heterogeneous samples. Of the 15 pre-clinical stage 0 studies, only six had formal ethical approval, and only five followed animal care policies. Both stage 1 studies and stage 1/2a studies failed to provide information on patient data confidentiality. Overall, no animal or human study reached the IDEAL-D stage endpoint.
CONCLUSION: FUS holds promise for enhancing drug delivery to the brain, but its development and implementation must adhere to rigorous safety standards using the established ethical and methodological frameworks. The complementary use of IDEAL-D, SYRCLE, and ROBINS-I tools indicates a high risk of bias and ethical limitations in both animal and human studies, highlighting the need for further improvements in study design for a safe implementation of FUS in neuro-oncology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:165 |
|---|---|
| Enthalten in: |
Acta neurochirurgica - 165(2023), 12 vom: 14. Dez., Seite 4259-4277 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thavarajasingam, Santhosh G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Brain tumor |
|---|
| Anmerkungen: |
Date Completed 22.12.2023 Date Revised 13.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00701-023-05782-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361697570 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361697570 | ||
| 003 | DE-627 | ||
| 005 | 20240114234744.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00701-023-05782-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1258.xml |
| 035 | |a (DE-627)NLM361697570 | ||
| 035 | |a (NLM)37672093 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Thavarajasingam, Santhosh G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Methodological and ethical challenges in the use of focused ultrasound for blood-brain barrier disruption in neuro-oncology |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2023 | ||
| 500 | |a Date Revised 13.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: Focused ultrasound (FUS) shows promise for enhancing drug delivery to the brain by temporarily opening the blood-brain barrier (BBB), and it is increasingly used in the clinical setting to treat brain tumours. It remains however unclear whether FUS is being introduced in an ethically and methodologically sound manner. The IDEAL-D framework for the introduction of surgical innovations and the SYRCLE and ROBINS-I tools for assessing the risk of bias in animal studies and non-randomized trials, respectively, provide a comprehensive evaluation for this | ||
| 520 | |a OBJECTIVES AND METHODS: A comprehensive literature review on FUS in neuro-oncology was conducted. Subsequently, the included studies were evaluated using the IDEAL-D framework, SYRCLE, and ROBINS-I tools | ||
| 520 | |a RESULTS: In total, 19 published studies and 12 registered trials were identified. FUS demonstrated successful BBB disruption, increased drug delivery, and improved survival rates. However, the SYRCLE analysis revealed a high risk of bias in animal studies, while the ROBINS-I analysis found that most human studies had a high risk of bias due to a lack of blinding and heterogeneous samples. Of the 15 pre-clinical stage 0 studies, only six had formal ethical approval, and only five followed animal care policies. Both stage 1 studies and stage 1/2a studies failed to provide information on patient data confidentiality. Overall, no animal or human study reached the IDEAL-D stage endpoint | ||
| 520 | |a CONCLUSION: FUS holds promise for enhancing drug delivery to the brain, but its development and implementation must adhere to rigorous safety standards using the established ethical and methodological frameworks. The complementary use of IDEAL-D, SYRCLE, and ROBINS-I tools indicates a high risk of bias and ethical limitations in both animal and human studies, highlighting the need for further improvements in study design for a safe implementation of FUS in neuro-oncology | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Brain tumor | |
| 650 | 4 | |a Focused ultrasound | |
| 650 | 4 | |a Glioblastoma | |
| 650 | 4 | |a Glioma | |
| 650 | 4 | |a IDEAL | |
| 650 | 4 | |a Neuro-oncology | |
| 650 | 4 | |a ROBINS-I | |
| 650 | 4 | |a SYRCLE | |
| 700 | 1 | |a Kilgallon, John L |e verfasserin |4 aut | |
| 700 | 1 | |a Ramsay, Daniele S C |e verfasserin |4 aut | |
| 700 | 1 | |a Aval, Leila Motedayen |e verfasserin |4 aut | |
| 700 | 1 | |a Tewarie, Ishaan Ashwini |e verfasserin |4 aut | |
| 700 | 1 | |a Kramer, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Van Vuurden, Dannis |e verfasserin |4 aut | |
| 700 | 1 | |a Broekman, Marike L D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta neurochirurgica |d 1950 |g 165(2023), 12 vom: 14. Dez., Seite 4259-4277 |w (DE-627)NLM00005609X |x 0942-0940 |7 nnns |
| 773 | 1 | 8 | |g volume:165 |g year:2023 |g number:12 |g day:14 |g month:12 |g pages:4259-4277 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00701-023-05782-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 165 |j 2023 |e 12 |b 14 |c 12 |h 4259-4277 | ||